logo-loader
RNS
MedPal AI plc

Result of General Meeting

RNS Number : 0602B
Medpal AI PLC
29 October 2026
 

29 October 2026

MedPal AI plc

("MedPal", the "Company" or the "Group")

Result of General Meeting

Issue of Warrants

 

Further to its announcement of 6 October 2026, MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, announces that announces that at the General Meeting of the Company held earlier today, all resolutions were duly passed. Accordingly, the Company has issued warrants to Clear Capital in relation to historical fundraises as shown below:

Number of Warrants

Exercise Price

Exercise Period

5,000,000

8p

the period ending on 8 October 2030

7,480,242

5.01p

the period ending on 3 March 2029

1,570,000

2.5p

the period ending on 26 March 2031

14,050,242

-

 

 

 

For further information please contact:

Enquiries:

MedPal AI plc

Jason Drummond, Chief Executive Officer

Via Square1 Consulting

Cairn Financial Advisers LLP (Nomad)

Louise O'Driscoll / Jo Turner

+44 (0) 20 7213 0880

Merlin Partners LLP (Broker)

 

+44 (0) 20 7839 3500

Clear Capital Markets Limited (Broker)

Bob Roberts

+44 (0) 20 3869 6080

Square1 Consulting - (Financial PR)

David Bick

+44 (0) 20 7929 5599 / +44 (0) 7831 381201

 

 

 

 

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a vertically integrated, AI-native digital health and pharmacy group. The Group operates NHS Distance Selling Pharmacy hubs at Sarus Court, Runcorn and Swaffham, New Health (new.co.uk), a dedicated GLP-1 weight management clinic, a B2B care home pharmacy supply business, eMARx, the Group's electronic medication administration record software for care homes, and Juno, an agentic AI health companion built on Anthropic's Claude. MedPal's ambition is to build the UK's leading Health OS: a single platform connecting prescribing, dispensing, delivery, administration and AI-driven patient support. The Company's LEI is 984500EDP8B0A14CBA61.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMPPGAAUUPQGAB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read